Mesothelioma Aid : Financial Plan For Mesothelioma Patients

Being diagnosed with mesothelioma can impose a heavy financial burden on both the patient and their family. Few patients can afford to completely pay their own way when it comes to treatment, relying on medical insurance to cover at least a portion of the cost; individuals who are uninsured or under insured, generally need to seek financial assistance from other sources. Although there is no typical cost for cancer care, it is not unusual for medical bills to escalate quickly beyond six figures.

Having the knowledge that resources are available, is the first step in coping financially with a diagnosis of mesothelioma. There are organizations and programs on the local, state and federal levels that can help, and compensation is also available to those diagnosed with mesothelioma through the manufacturers of the products that caused their illness. Making sound financial decisions for the future of your family is important, and addressing these issues early on will give you the peace of mind to concentrate fully on your medical care.

Paying For Your Treatment

Part of dealing with mesothelioma realistically involves thinking through how you will pay for your treatment, and ultimately, how your family will be taken care of. Diagnosis, treatment and sometimes support services are expensive, and you may not be able to work full-time during this period, or you may be retired.

Without insurance it may be difficult to obtain the medical treatment of your choice, and even people who have medical insurance will need to do some finanical planning at this time. Resolving financial issues early on will lift the burden of worrying about your medical care and the well-being of your family.

If you are covered under an individual or group health plan, you should talk with your claims representative to find out exactly what your plan will cover. Plans can vary greatly on what types of treatment are covered, on the length of hospital stays and on the amount you must pay before your coverage begins. Some plans cover home care services, others do not.

If you are over the age of 65 or are disabled, the Medicare program may provide some health care benefits. Many people on Medicare have supplemental insurance policies to cover what Medicare does not. You can inquire about your eligibility for Medicare by contacting your local Social Security Office or the Medicare Hotline,1-800-MEDICARE (1-800-633-4227). Some people on Medicare are also eligible for Medicaid. You can find out about eligibility requirements for their services by contacting your state or local department of social services or through the federal government's Centers for Medicare and Medicaid Services (formerly known as the Health Care Financing Administration) website at http://www.cms.hhs.gov/

Financial compensation may also be available to mesothelioma patients and their families through claims against the manufacturers of products which contained asbestos. It is widely acknowledged that asbestos is the cause of mesothelioma. For more information on your legal rights, legal services and compensation for which you may be eligible, contact a mesothelioma lawyer.

to be continued...

Read More...

Alimta (Pemetrexed) Mesothelioma Treatment

In July 2002, The U.S. Food and Drug Administration and Eli Lilly Company announced that Alimta (pemetrexed) would be made available to patients with malignant pleural mesothelioma. The drug, a chemotherapy treatment is not fully FDA approved but will be made available to "qualified patients who have been diagnosed with malignant pleural mesothelioma and have not yet received treatment." The FDA allows Alimta to be used under a so-called "Expanded access program," that allows new treatments available to patients with diseases like mesothelioma, for which there is no other treatment or satisfactory alternative therapy. Under this program, patients with mesothelioma will be given access to Alimta while the FDA review process is going forward and the treatment is pending review.

The FDA agreed to allow patients use of Alimta under the "expanded access program" based on the initial results from clinical trials. The results of a Phase III trial discussed at the annual meeting of the American Society of Clinical Oncology, showed that patients treated with Alimta and cisplatin had better survival rates, had less pain and shortness of breath. Pemetrexed (Alimta) is a new antifolate, a type of drug that targets the folic acid metabolic pathway, inhibiting the availability of certain B complex vitamins. The downside, in the trial was that in some patients there was decrease in the number of white blood cells used to fight infections.

The clinical trial was the largest ever conducted in the US for a mesothelioma treatment.

The findings: Tumors shrank in 41 percent of patients on Alimta (pemetrexed) in combination cisplatin, a more common chemotherapy treatment. Cisplatin resulted reduced to tumors in 17 percent of patients receiving it. Patients on the Alimta (pemetrexed) cisplatin combination lived nearly three months longer than those on cisplatin alone.

According to lead author of the study, Nicholas J. Vogelzang, M.D., University of Chicago Cancer Research Center, "This is the largest clinical trial ever conducted in this disease and the 25 to 30 percent improvement in survival for patients on the combination therapy is the first time anyone has documented a significant improvement in patients treated for mesothelioma."

Under the current expanded access program, Alimta may be available free to patients who qualify. Additionally, patients with mesothelioma may be entitled to large settlements against employers or asbestos makers.

If you would like more information about Mesothelioma or your legal rights please contact us here.

Read More...

Innovative Treatments For Mesothelioma Patients

Aside from the standard or traditional treatment options for mesothelioma patients, the following are the innovative treatment options that can be applied accordingly to the patient:

Alimta (pemetrexed) now available to patients with malignant pleural mesothelioma. New chemotherapy drug treatment....read more.

Photodynamic Therapy
Photodynamic therapy (PDT), a type of cancer treatment, is premised in the theory that single-celled organisms, if first treated with certain photosensitive drugs, will die when exposed to light at a particular frequency. Through PDT, doctors attempt to destroy cancerous cells through the use of fixed frequency light to activate photosensitizing drugs that have accumulated in body tissues.

In PDT, a doctor administers photosensitizing drug intravenously. In a matter of days, the drug selectively concentrates in diseased cells, while rapidly being eliminated from normal cells. Doctors then expose the treated cancer cells to a laser light chosen for its ability to activate the photosensitizing agent. Doctors deliver this laser light to the cancer site, (in the case of mesothelioma, the pleura), through a fiberoptic device that allows the doctor to control the laser light. As the agent in the treated cells absorbs the light, an active form of oxygen destroys the surrounding cancer cells. A doctor must carefully time the light exposure so that it occurs when most of the photosensitizing drug has left the healthy cells, but remains present in cancerous ones.

Skin sensitivity is the major side effect of PDT. Doctors usually advise patients undergoing this type of therapy to avoid direct and even indirect sunlight for at least six weeks. Other side effects may include nausea, vomiting, a metallic taste in the mouth, and eye sensitivity to light.

Immunotherapy
Immunotherapy is designed to repair, stimulate, or enhance the immune system's natural anticancer function. Through immunotherapy, sometimes called biological therapy, doctors use the body's own immune system to protect against disease. Researchers have found that the immune system may recognize the difference between healthy cells and cancer cells, and eliminate those that become cancerous.

Substances used in immunotherapy, called biological response modifiers (BRMs) alter the interaction between the body's immune defenses and cancer, thereby improving the body's ability to fight disease. Some BRMs, such as cytokines and antibodies, occur naturally in the body, however, pharmaceuticals can now make BRMs in the laboratory that imitate or influence natural immune response agents. These BRMs may enhance the immune system to fight cancer cell growth, eliminate, regulate, or suppress the body's responses that permit cancer growth, make cancer cells more susceptible to destruction by the immune system, alter cancer cell's growth patterns to behave like normal cells, block or reverse the process that changes a normal cell into a cancer cell, and prevent a cancer cell from spreading to other sites. BRMs doctors currently used in cancer treatment include interferons, interleukins, tumor necrosis factor, colony-stimulating factors, monoclonal antibodies, and cancer vaccines.

Specific immunotherapy research has concentrated on the SV40 virus. Some researchers believe that the presence of this virus makes the formation of mesothelioma tumors more likely. Having identified this virus, researchers now hope to develop a vaccine, which could prevent the development of mesothelioma in those a risk by prompting the body to produce antibodies that would attack the SV40 virus.

Gene Therapy
Gene therapy treats mesothelioma, and other diseases, by manipulating an individual's genes to achieve a therapeutic goal. The premise of gene therapy is based on correcting disease at the DNA level and compensating for the abnormal genes.

Replacement gene therapy replaces a mutated or missing gene, most often a tumor suppressor gene, with a normal copy of that gene to keep cell growth and division under control. The most common gene mutated in cancer has become a prime target for gene replacement. Researchers have met with some success in inhibiting cell growth, inhibiting angiogenesis (the development of a tumor's blood supply), and inducing apoptosis (cell death). Knockout gene therapy targets the products of oncogenes (a gene that can induce tumor formation) in an effort to render them inactive and reduce cell growth.

Brachytherapy

Innovative new radiation treatment, that is less invasive....read more

Alternative Medicine
Complementary and alternative medicine covers a wide range of treatments that conventional medicine does not commonly accept or make available to its patients. Acupuncture, herbs, homeopathy, therapeutic massage, and Far Eastern medicine are among those treatments considered alternative.

Patients can use these therapies alone as an alternative to conventional medicine, or in addition to conventional medicine. Many focus on treating the whole patient ­ physically, mentally, emotionally, and spiritually. These treatments are not generally used in hospitals, and, for the most part, are not covered under insurance policies.

Read More...

Mesothelioma Updates : New Technology To Detect Asbestos-Related Lung Disease

Michael Harbut, M.D., MPH, co-director of the National Center for Vermiculite and Asbestos-Related Cancers (NCVAC) at the Barbara Ann Karmanos Cancer Institute in Detroit, MI, and chief of the Center for Occupational and Environmental Medicine Wayne State University, announced the use of a new technology to aid in the diagnosis of asbestos-related lung disease. The announcement was made at the Asbestos Disease Awareness Organizations annual conference, Saturday, March 28, in Manhattan Beach, CA.

"Radiographic approaches developed by Carmen Endress, M.D., FACR, Associate Professor of Radiology, Wayne State University School of Medicine and radiologist at the NCVAC, allow us to visualize lesions caused by asbestos exposure in three dimensional detail and often at a much earlier stage than that of the current standard radiographic techniques," said Harbut.

This new approach involves taking images obtained on the 64-slice high resolution CT scan and enhancing them using the Vitrea imaging software program developed by Vital Images, Inc.

Harbut explained, "The benefits of this new approach include the possibility of earlier detection; better differentiation between patients with scarring on the lungs and other diseases; assistance in determining why some people who have thickening on the covering of the lungs have uncontrolled, unrelenting pain; and potentially increased success in the overall diagnosis and treatment of asbestos-related disease.

According to Harbut, this approach could also have a significant public-health impact.

If we can identify the sentinel or first cases of asbestosis or lung cancer at an early stage, then we can help identify asbestos exposures in places where it might not have previously been suspected. Such identification of early detection could help to reduce the death rate from asbestos-related diseases."

Harbut added that this new technology approach to chest radiography could also help reduce cases of fraud which have been reported in asbestos litigation, due to the clarity and sophistication of the images that can help identify which cases are asbestos-related and which are not.

Dr. Endress added, "Its my sincere hope that with this new approach and enhanced technology we will help reduce the death rate caused by asbestos-related diseases, reduce the suffering by patients and their loved ones, and make a significant contribution to medicine."

The use of this technology in the diagnosis and treatment of asbestos-related cancers and high-malignancy potential asbestos-related diseases represents another first for Karmanos Cancer Institute scientists and physicians. Previously, NCVAC researchers were among the first to discover the value of osteopontin a tumor marker of mesothelioma and published this finding in the New England Journal of Medicine. Karmanos workers have also reported the potential value of soluble mesothelin-related peptide, another tumor marker, in screening for mesothelioma.

Michael Harbut, M.D., MPH, Chief of the Center for Occupational and Environmental Medicine, is co-director of the National Center for Vermiculite and Asbestos-Related Cancers at the Barbara Ann Karmanos Cancer Institute, in Detroit, MI. In response to the United States Environmental Protection Agency's (EPA) identification of major sources of public asbestos exposure in Michigan, and to address the need for early diagnosis and aggressive treatment of asbestos-related diseases, the Barbara Ann Karmanos Cancer Institute and the Center for Occupational and Environmental Medicine (COEM) affiliated with Wayne State University, joined forces to establish The National Center for Vermiculite and Asbestos-Related Cancers (NCVAC). COEM has had a long interest in asbestos-related diseases and the Karmanos Cancer Institute is heavily involved in both clinical and basic research on asbestos-related cancers enabling the two centers to rapidly bring together the expertise and resources necessary to study the problem immediately.

Source: Karmanos Cancer Institute

Read More...